liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Biomarkers of diabetic nephropathy: A 2017 update
Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för kardiovaskulär medicin. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Hjärt- och Medicincentrum, Endokrinmedicinska kliniken. University of Athens, Greece.
University of Athens, Greece.
Henri Dunant Hospital, Greece.
University of Athens, Greece.
Vise andre og tillknytning
2017 (engelsk)Inngår i: Critical reviews in clinical laboratory sciences, ISSN 1040-8363, E-ISSN 1549-781X, Vol. 54, nr 5, s. 326-342Artikkel, forskningsoversikt (Fagfellevurdert) Published
Abstract [en]

Diabetic nephropathy (DN), also named diabetic kidney disease (DKD), is a devastating complication in patients with both type 1 and 2 diabetes mellitus (T1D and T2D) and its diagnosis has been traditionally based on the presence of micro-albuminuria (MA). The aim of this article is to update, through review of the relevant medical literature, the most promising biomarkers for early DKD detection. MA has historically been employed as an early marker of microvascular complications, indicating risk for advanced CKD. However, due to the inability of MA to adequately predict DKD, especially in young patients or in non-albuminuric DKD, additional biomarkers of glomerular and/or tubular injury have been proposed to uncover early renal dysfunction and structural lesions, even before MA occurs. Defining new predictive biomarkers to use alongside urinary albumin excretion (UAE) during the initial stages of DKD would provide a window of opportunity for preventive and/or therapeutic interventions to prevent or delay the onset of irreversible long-term complications and to improve outcomes by minimizing the rates of severe cardio-renal morbidity and mortality in DKD patients.

sted, utgiver, år, opplag, sider
TAYLOR & FRANCIS LTD , 2017. Vol. 54, nr 5, s. 326-342
Emneord [en]
Diabetic nephropathy; diabetic kidney disease; diabetes; biomarkers
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-143113DOI: 10.1080/10408363.2017.1377682ISI: 000414146600003PubMedID: 28956668OAI: oai:DiVA.org:liu-143113DiVA, id: diva2:1159355
Tilgjengelig fra: 2017-11-22 Laget: 2017-11-22 Sist oppdatert: 2025-02-10

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Person

Papadopoulou-Marketou, Nektaria

Søk i DiVA

Av forfatter/redaktør
Papadopoulou-Marketou, Nektaria
Av organisasjonen
I samme tidsskrift
Critical reviews in clinical laboratory sciences

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 254 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf